Cetera Investment Advisers
NVCR icon

Cetera Investment Advisers’s NovoCure NVCR Stock Holding History

Cetera Investment Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,042
Closed -$231K – 1849
2021
Q2 		$231K Buy
+1,042
New +$203K ﹤0.01% 1583

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Investment Advisers's NVCR Position: Q3 2021 in Review

Cetera Investment Advisers sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 1,042 shares — an estimated $231K sold.

Cetera Investment Advisers first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $231K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Cetera Investment Advisers reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Cetera Investment Advisers sold 1,042 NovoCure shares in Q3 2021, an estimated $231K.
  • Cetera Investment Advisers first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
  • Cetera Investment Advisers's NovoCure position peaked at $231K in Q2 2021.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Cetera Investment Advisers's 13F filing for Q3 2021, filed 16 Nov 2021.